Annual treatment costs for empagliflozin 25 mg in PIONEER 2 and sitagliptin 100 mg in PIONEER 3 were estimated to be USD 6000 and USD 5493, respectively, while annual treatment costs with liraglutide 1.8 mg in PIONEER 4 were estimated to be USD 11,367, with needle costs accounting for USD 144 of this total (Fig

collapse Signs of sepsis: high fever or very low temperature, rapid breathing, confusion, or feeling extremely unwell following an injection Severe hypoglycaemia with loss of consciousness or inability to swallow Severe chest pain or significant difficulty breathing Contact your GP or a healthcare professional promptly if you experience: Injection site reactions such as persistent redness, swelling, warmth, or pain, which may indicate infection or an inflammatory response Systemic symptoms including fever, chills, or malaise following administration Gastrointestinal symptoms such as severe or persistent nausea, vomiting, or abdominal pain these are known effects associated with GLP-1 receptor agonism and may require clinical assessment [15] [6] Symptoms of hypoglycaemia shakiness, sweating, confusion, or palpitations particularly if retatrutide is being used alongside other glucose-lowering agents Cardiovascular symptoms such as a rapid or irregular heartbeat Report suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk

Our team strongly advises against it
Decotiis concludes
(4) Given the inherent heterogeneity and potential reporting bias in the FAERS database, we conducted a series of sensitivity analyses
Unmanaged diabetes can damage the kidneys over time